Log In
BCIQ
Print this Print this
 

Biosimilar erythropoietin, epoetin alfa (Abseamed)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionBiosimilar version of erythropoietin (EPO)
Molecular Target Erythropoietin (EPO) receptor
Mechanism of ActionErythropoietin (EPO) receptor agonist; Biosimilar
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationAnemia
Indication DetailsTreat anemia
Regulatory Designation
PartnerMedice Arzneimittel Pütter GmbH & Co.KG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today